Olaparib was originally approved in capsule formulation (50mg) in the EU in 2015, for the maintenance treatment of adults with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Olaparib tablets (100mg and 150mg) have been approved for use in the same indication, but regardless of BRCA status, therefore can be used in a wider population. This new presentation will also allow for fewer dose units.
Pharmacists should ensure that the correct formulation and dose is dispensed to patients, and patients should be advised on the correct dose. The differences in the doses for tablets and capsules should be explained to any patient switching between the two.